Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
2001-03-30
2004-08-24
Dodson, Shelley A. (Department: 1616)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
C427S002300
Reexamination Certificate
active
06780424
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention relates to a system for controlled drug release within a vessel lumen, and to a method and to a device for controlled drug release.
A device for providing a continuous release of drugs over an extended period of time following from a single administration of a drug releasing material has wide application in treating disease. One type of continuous drug release mechanism is based upon degradation of biodegradable polymers. The biodegradable polymers have drugs incorporated within them. As the biodegradable polymers hydrolyze over time, the drugs are released. Hydroxycarboxylic acid polymers have been used to release drugs in this manner.
One other modality of drug release is a prolonged, though discontinuous release of drugs. Frequently, with a discontinuous release, there is a lag phase of no or negligible drug release when a drug delivery device is delivered to an in situ site for drug release.
One problem with sustaining drug release is that when drugs, particularly water soluble drugs, are incorporated into polymers, it is difficult to prevent a rapid, uncontrolled release of the drugs. As used herein, the term “water soluble drug” is defined as a hydrophilic compound with a solubility in water greater than 1 percent (w/v) and that is practically insoluble in nonpolar organic solvents such as ethyl acetate, methylene chloride, chloroform, toluene, or hydrocarbons. This rapid, uncontrolled release from a drug-polymeric matrix is known as a “burst effect.” The burst effect is particularly troublesome with high drug loading.
One other type of uncontrolled drug release is characterized by a “lag effect.” The lag effect occurs when the rate of drug release decreases to a negligible value.
The degree of drug release from a polymeric-drug matrix is, in part, controlled by the morphology of the polymeric-drug matrix. The morphology is, for some embodiments, a single-phase dispersion and for other embodiments, is a multi-phase dispersion. A single-phase dispersion is typically transparent when viewed in natural light. The single phase dispersion is clear and transparent because both the drug and the polymer have a mutual miscibility. A multi-phase dispersion has micro domains that give the dispersion a cloudy appearance. For some multi-phase dispersions, drugs are embedded in a polymeric matrix as particles.
Drug release is also controlled by the degree of drug loading. Matrices that have dispersed drug particles that do not contact each other tend to have a slow release of drug. A drug carrier such as blood is typically required to move the drug through the matrix and into the bloodstream of a living being.
Drug-polymeric matrices have been used to deliver drugs in situ through a vehicle such as a stent. The drug-polymeric matrix has been applied as a coating or a wrap to the stent. U.S. Pat. No. 5,605,696, which issued Feb. 25, 1997, describes a drug loaded polymeric material that is applied to an intravascular stent. The drug-polymeric matrix defines pores, multilayered to permit a combination of different drugs in a single stent. The stent also includes a rate controlling membrane that controlled retention and delivery of selected drugs to the affected blood vessel. The drug is dispersed as small particles, having a maximum cross-sectional dimension of 10 microns.
REFERENCES:
patent: 2072303 (1937-03-01), Herrmann et al.
patent: 4882168 (1989-11-01), Casey et al.
patent: 4977901 (1990-12-01), Ofstead
patent: 5292516 (1994-03-01), Viegas et al.
patent: 5298260 (1994-03-01), Viegas et al.
patent: 5300295 (1994-04-01), Viegas et al.
patent: 5306501 (1994-04-01), Viegas et al.
patent: 5328471 (1994-07-01), Slepian
patent: 5330768 (1994-07-01), Park et al.
patent: 5462990 (1995-10-01), Hubbell et al.
patent: 5464650 (1995-11-01), Berg et al.
patent: 5578073 (1996-11-01), Haimovich et al.
patent: 5605696 (1997-02-01), Eury et al.
patent: 5628730 (1997-05-01), Shapland et al.
patent: 5658995 (1997-08-01), Kohn et al.
patent: 5667767 (1997-09-01), Greff et al.
patent: 5670558 (1997-09-01), Onishi et al.
patent: 5700286 (1997-12-01), Tartaglia et al.
patent: 5716981 (1998-02-01), Hunter et al.
patent: 5746998 (1998-05-01), Torchilin et al.
patent: 5800392 (1998-09-01), Racchini
patent: 5824049 (1998-10-01), Ragheb et al.
patent: 5830178 (1998-11-01), Jones et al.
patent: 5837313 (1998-11-01), Ding et al.
patent: 5851508 (1998-12-01), Greff et al.
patent: 5865814 (1999-02-01), Tuch
patent: 5873904 (1999-02-01), Ragheb et al.
patent: 5925720 (1999-07-01), Kataoka et al.
patent: 5955509 (1999-09-01), Webber et al.
patent: 5971954 (1999-10-01), Conway et al.
patent: 5980928 (1999-11-01), Terry
patent: 5980972 (1999-11-01), Ding
patent: 6001382 (1999-12-01), Levy
patent: 6010530 (2000-01-01), Goicoechea
patent: 6015541 (2000-01-01), Greff et al.
patent: 6060518 (2000-05-01), Kabanov et al.
patent: 6096070 (2000-08-01), Ragheb et al.
patent: 6153252 (2000-11-01), Hossainy et al.
patent: 6165212 (2000-12-01), Dereume et al.
patent: 0 665 023 (1995-08-01), None
patent: 0 970 711 (2000-01-01), None
patent: WO 91/12846 (1991-09-01), None
patent: WO 97/45105 (1997-12-01), None
patent: WO 99/63981 (1999-12-01), None
patent: WO 00/12147 (2000-03-01), None
patent: WO 00/64506 (2000-11-01), None
patent: WO 01/01890 (2001-01-01), None
patent: WO 01/17577 (2001-03-01), None
patent: WO 01/45763 (2001-06-01), None
patent: WO 01/74414 (2001-10-01), None
Aoyagi, T., et al., “Preparation of cross-linked aliphatic polyester and application to thermo-responsive material”,Journal of Controlled Release, vol. 32, 87-96, (1994).
Chung, J.E., et al., “Inner core segment design for drug delivery control of thermo-responsive polymeric micelles”,Journal of Controlled Release, vol. 65, 93-103, (2000).
Inoue, T., et al., “An AB block copolymer of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drugs”,Journal of Controlled Release, vol. 51, 221-229, (1998).
Kataoka, K., et al., “Block copolymer micelles as vehicles for drug delivery”,Journal of Controlled Release, vol. 24, 119-132 (1993).
Liu, H., et al., “Drug release characteristics of unimolecular polymeric micelles”,Journal of Controlled Release, vol. 68, 167-174, (2000).
Yokoyama, M., et al., “Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor”,Journal of Controlled Release, vol. 50, 79-92, (1998).
Barath et al.,Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury; JACC vol. 13, No. 2; Feb. 1989:252A (Abstract).
Matsumaru et al.,Embolic Materials For Endovascular Treatment of Cerebral Lesions; J. Biomater. Sci. Polymer Edn, vol. 8, No. 7 (1997), pp. 555-569.
Miyazaki et al.,Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice, Chem. Pharm. Bull. 33(6) (1985), pp. 2490-2498.
Miyazawa et al.,Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat; J. Cardiovasc. Pharmacol. (1997), pp. 157-162.
Ohsawa et al.;Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty; American Heart Journal (Dec. 1998); pp. 1081-1087.
Pechar et al.,Poly(ethylene glycol)Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin, Bioconjugate Chemistry, Mar/Apr. 2000, pp. 131-139; vol. 11, No. 2, Published by American Chemical Society.
Shigeno,Prevention of Cerebrovascular Spasm by Bosentan, Novel Endothelin Receptor; Chemical Abstract 125:212307 (1996).
Marconi et al.,Covalent bonding of heparin to a vinyl copolymer for biomedical applications, Biomaterials, 18(12):885-890 (1997).
Dodson Shelley A.
George Konata M
Squire Sanders & Dempsey
LandOfFree
Controlled morphologies in polymer drug for release of drugs... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Controlled morphologies in polymer drug for release of drugs..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlled morphologies in polymer drug for release of drugs... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3309083